Abstract:Background Patients with obesity experience an increased duration of labor with increased risk of perinatal morbidity. Compared to parturients without obesity, they also experience fewer uterine contractions after administration of misoprostol. It is unclear whether the same dose of misoprostol should be used for induction of labor in patients with obesity compared to non-obese patients. Therefore, we sought to investigate if a higher dose of misoprostol for patients with obesity is more effective. Objective To determine if 50mcg compared to 25mcg of vaginal misoprostol reduces the time from induction start to delivery in patients with obesity. Study Design We performed a double-blinded, pragmatic randomized controlled trial, between June 1, 2022, and July 17, 2023. Patients with a body mass index (BMI) ≥ 30 kg/m 2 undergoing labor induction ≥ 36 weeks, singleton gestations, and a cervical dilation ≤ 3cm on admission, were included. Patients were excluded if they had a contraindication to vaginal delivery or misoprostol administration. Patients were randomized to 25 or 50 mcg of vaginal misoprostol, stratified by parity, BMI < 40 kg/m 2 or ≥ 40 kg/m 2 , and provider intent to use mechanical dilation at the onset of labor induction. Usual labor management was followed at the discretion of the provider. The primary outcome was time from induction to delivery. A priori, we estimated 90 subjects per group (N=180) were needed for an 85% power to detect a 3-hour difference between groups with a type I error of 5%. Analysis was intention-to-treat. A two-sample t-test was used for the primary outcome, Cohen's d as a measure of effect, and P values were reported. Results Of the 180 patients randomized, 88 were assigned to the 25mcg group and 92 were assigned to the 50mcg group. 96.1% of patients received the designated intervention. Baseline characteristics were similar between groups. No difference was found in the primary outcome of time to delivery (21.6 hours vs. 18.6 hours; d = 0.28; 95% confidence interval, -0.02-0.57). In a planned subgroup analysis, multiparous patients delivered faster in the 50mcg group (15.2 hours vs. 12.0 hours; d = 0.51; 95% confidence interval, 0.04-0.97). The risk of tachysystole associated with fetal heart tracing changes was rare overall (2.2%) and not significantly different between groups. No differences in maternal or neonatal adverse effects were observed. Conclusion Patients with obesity undergoing cervical ripening with 50mcg of vaginal misoprostol experienced similar time to delivery when compared to 25mcg. However, multiparous patients had a significantly reduced time to delivery when 50mcg was used. A higher dose of misoprostol may be a promising intervention for reducing time in labor which warrants further study.

Misoprostol as Oral Solution or Oral Tablet for Induction of Labour (MISOBEST): A Randomised Controlled Non‐Inferiority Trial

Comparison of Misoprostol for Labor Induction: Vaginal Insert Versus Oral Application Concerning Efficiency and Safety

Vaginal misoprostol versus vaginal dinoprostone for cervical ripening and induction of labour: An individual participant data meta‐analysis of randomised controlled trials

Vaginal Compared With Oral Misoprostol Induction at Term: A Cluster Randomized Controlled Trial

Oxytocin vs oral misoprostol for PROM induction in nulliparas with unfavorable cervix: a randomized trial

Misoprostol versus prostaglandin E2 gel for labor induction in premature rupture of membranes after 34 weeks of pregnancy

Vaginal dinoprostone insert compared with two different oral misoprostol regimens for labor induction in nulliparous and multiparous women

Comparison of the Effectiveness and Pregnancy Outcomes of Labor Induction with Dinoprostone or Single-Balloon Catheter in Term Nulliparous Women with Borderline Oligohydramnios

Low-Dose Oral Misoprostol Versus Oxytocin Infusion For Induction Of Labor In Pregnant Women With Term Premature Rupture Of Membranes in China: A retrospective Nested Case-Control Study

Comparison of two labor induction regimens with intravaginal misoprostol 25 μg and adverse perinatal outcomes

Outpatient labor induction—Exploring future potential by assessing eligibility in a historical cohort

Optimal Misoprostol Dosing Among Patients with a BMI Greater Than 30: A Randomized Controlled Trial

First dose of misoprostol administration at home or in hospital for medical abortion between 12-22 gestational weeks in Sweden (PRIMA): a multicentre, open-label, randomised controlled trial

Misoprostol in Labour Induction of Term Pregnancy:A Meta-Analysis

A Randomized Study of Two Doses of Misoprostol in Combination with Mifepristone for Inducted Labor in Second-trimester Pregnancy

A Comparison of the Efficacy and Safety of Mifepristone and Misoprostol Versus Misoprostol alone for Induction of Labour in Nigerian Women with Intrauterine Fetal Death: A Triple Blind Randomized Controlled Trial

Comparative study of second‐line labor induction methods in patients with unfavorable cervix after first‐line low‐dose oral misoprostol

Labor Induction with Prostaglandin or Oxytocin? A Retrospective Matched Case Study

Patient experience in prostaglandins-induced cervical ripening: A comparative study using a standardized questionnaire

Medical treatment of miscarriage using misoprostol-a retrospective study

Vaginal dinoprostone vs Foley catheter for induction of labor at term with an unfavorable cervix: an open-label randomized controlled trial